Main Menu
12
Oct
2004

Children with Rare Disorder Lead Scientists to Cancer Related Gene

     

Tuesday 12 October 2004

 

In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.

The team led by Dr Nazneen Rahman has been studying children with a rare genetic disorder to discover what causes their cells to divide incorrectly and to find out whether there are links to similar errors that occur in many cancers.

This unique approach has now led scientists to the groundbreaking discovery that mutations in the BUB1B gene result in cells having the wrong number of chromosomes, which in turn can lead to cancer in children.

Normal cells have 46 chromosomes and a cell with more or less than this number it is said to be aneuploid. Aneuploidy is very common in many cancers, but until now, scientists have not been sure whether it is a symptom or cause of the cancer. However this new study shows that mutations in the BUB1B gene cause aneuploidy and a high risk of cancer.

Dr Rahman’s team at The Institute studied a group of eight families with a very rare disorder called Mosaic Variegated Aneuploidy (MVA) syndrome. In five families the children had two mutations in the BUB1B gene, which led to many of their cells having the wrong number of chromosomes. The children had a variety of problems such learning difficulties and heart defects and two developed cancer.

Dr Nazneen Rahman, Team Leader in Cancer Genetics at The Institute of Cancer Research comments:

“This study has been extremely valuable, not only in helping us understand the cause of MVA, but in demonstrating that aneuploidy, the loss or gain of chromosomes, is not merely a symptom of many cancers, but may well be a cause. We are very excited at the prospect of future studies to see if the BUB1B gene is involved in generating aneuploidy in common cancers that occur in otherwise healthy people. “

Professor Peter Rigby, Chief Executive of The Institute of Cancer Research comments:

“The discovery of this gene is groundbreaking research that reinforces
The Institute's reputation as the world leader in cancer genetics. It provides us with new insight into what is probably an important mechanism in the development of many cancers, and we look forward to future results.”

 

- ends -

 

For further information, or to arrange interviews, please contact:
Marie MacLean
Press Officer
Institute of Cancer Research
Tel: 020 7153 5359
Email: [email protected]

Notes to editors

  1. The Institute of Cancer Research is a centre of excellence with leading scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care.
  2. The Institute is a charity that relies on voluntary income. The Institute is a highly cost-effective major cancer research organisation with over 90p in every £ directly supporting research.

Please note:
Unfortunately the press office are unable to answer queries from the general public. For general cancer information please refer to The Institute's cancer information page.

comments powered by Disqus